Thursday, 22 Jun 2017

You are here

Chondroitin Effective in Knee OA. Or is it?

Reginster and colleagues have reported on the results of the CONCEPT trial showing that osteoarthritis (OA) patients treated 800 mg/day of  pharmaceutical-grade chondroitin sulfate (CS) have less VAS pain scores and improved function over 6 months therapy. These results were superior to placebo and equivalent to celecoxib in reducing in symptomatic OA knee pain.

They enrolled 603 OA knee patients a 6-month, 3-arm, double-blind, double-dummy trial were patients were randomized to either placebo, CS and celecoxib (200 mg/day). After 6 mos, greater improvement in Pain VAS scores were seen with CS (-42.6 mm) and celecoxib (−39.5 mm) versus those treated with placebo (−33.3 mm) (p=0.001 for CS and p=0.009 for celecoxib vs PBO).

Figure 2 

So is chondroitin as effective as NSAID therapy?  The problem is that many prior studies of CS use in knee OA have yielded mixed results. ( Citation source: http://buff.ly/2rqc0hE)

These data are limited by fair low effect size, the trial being sponsored by the CS manufacturer and prior claims showing selective benefit of a specific manufacturer compared to other manufacturers.

While the results are encouraging, further study by other parties is advisable.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Bone Turnover Markers in Practice: A Guide for the Rheumatologist

Bone turnover markers (BTMs) have been eyed for decades as potential monitoring tools in osteoporosis.

However there have been difficulties with poor between-lab reproductivity, insufficiently controlled heterogeneity, and pre-analytical variability of the assays; making BTMs vastly unpopular amongst practicing rheumatologists.

2017 ACR Guideline on Glucocorticoid-Induced Osteoporosis

The American College of Rheumatology has updated its 2010 guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. The guideline provides recommendations on assessing fracture risk and treatment for adults and special patient populations, including women of childbearing potential, adults treated with very high-dose glucocorticoids, adults with organ transplants, and children ages 4-17.

Higher Fracture Risks with Prolonged Bisphosphonate Use in Older Women

The Journal of the American Geriatric Society has reported that older women receiving bisphosphonate therapy for greater than 10-13 years were more likely to suffer from fractures.

High Fiber Intake May Decrease Osteoarthritis Knee Pain

 

Dai, Felson and colleagues report in Annals of Rheumatic Disease that high dietary fiber lowers the risk of symptomatic osteoathritis (SxOA), but the radiographic benefits remain unclear. (Citation source http://buff.ly/2rHv9yd)

Anti-Sclerostin Drug Hampered by Heart Problems

Reuters reports that FDA approval of romosozumab (brand name Evenity) may be held up because of higher rates of cardiac events seen in a late-stage clinical trial.